Navigation Links
Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
Date:9/15/2011

biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the driving characteristics of the best employers and to identify the 20 best employers from a universe of about 200 companies.  Respondents to the web-based survey were asked to rate companies based on 23 characteristics, including financial strength, easy adaptation to change, and a research-driven environment.

According to Science, the 2011 global survey results were based on 3,784 responses from North America (80%), Europe (12%), and Asia/Pacific Rim (6%).  A mathematical process was used to assign a unique score to rate each company's employer reputation.

About Regeneron Pharmaceuticals Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on www.regeneron.com.Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.a
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
2. Regeneron Reports Second Quarter 2011 Financial and Operating Results
3. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
4. Trading in Regeneron Common Stock Halted
5. Regeneron Reports First Quarter 2011 Financial and Operating Results
6. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
8. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
9. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
10. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
11. Regeneron Announces March 2011 Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Roughly three-quarters of pharmacists said they ... interchangeable biosimilar for its branded biologic counterpart if ... according to a survey published in the Academy ... Managed Care & Specialty Pharmacy (JMCP). ... would feel as confident if the products had ...
(Date:2/27/2015)... -- Pomerantz LLP is investigating claims on behalf of investors ... VTAE ).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... directors have violated Sections 10(b) and 20(a) of the ... February 27, 2015, the Company announced that its partner ...
(Date:2/27/2015)... TEL-AVIV , Israele, February 27, 2015 /PRNewswire/ ... continua nel suo sviluppo dell,innovativo sistema di monitoraggio ... il primo trial sull,uomo-   ... operante nello sviluppo di nuovo sistema per il ... congestizio (CHF), ha annunciato oggi di aver concluso ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
(Date:3/1/2015)... 2015 A federal court overseeing ... scheduled to go to trial in October has ... to provide testimony regarding the role an Italian ... Profemur device, Bernstein Liebhard LLP comments. According to ... District of Iowa on February 25th, Wright Medical ...
(Date:3/1/2015)... 01, 2015 The number of transvaginal ... the past few weeks in two New Jersey litigations ... claims, the Firm announces. , A Case List ... the Bergen County proceeding established for products manufactured by ... few weeks earlier, when 90 fewer cases had been ...
(Date:3/1/2015)... 2015 ERISAPros is pleased ... Roddy to the professional staff of its Compliance Department. ... The Ohio State University-Mortiz College of Law. Prior to ... working with several Fortune 500 companies as well as ... corporate benefits. Her experiences range from benefit plan design, ...
(Date:3/1/2015)... Theme and plugin developers from Pixel Film ... for Final Cut Pro X entitled Transccordion. , “Transccordion ... FCPX editors project.” Said Christiana Austin, CEO of Pixel ... to easily drag and drop their accordion transition between ... controls over the parameters of this transition bundle and ...
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims ... platform and gears towards the goal for a better ... group talks in smaller groups will be held after ... Development, Leadership, Entrepreneurship, Healthcare, Social and Volunteerism, Women and ... youths. , Young adults aged between 18-30 ...
Breaking Medicine News(10 mins):Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4
... 2011 Horst Sievert, MD, PhD, a renowned ... O. Hartzler Master Clinical Operator Award in a ... Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the ... given each year to a physician who has ...
... Nov. 11 (HealthDay News) -- Age-related declines in physical ... a new study. "The more income and assets ... co-author Virginia Richardson, a professor of social work at ... The researchers analyzed data from roughly 6,500 participants ...
... -- ,Helping others can reduce cravings for alcohol and ... study suggests. Such cravings are major causes of ... noted. The study included 93 male and 102 ... courts for substance abuse treatment at a large facility ...
... a new oral cholera vaccine developed through the ... by the United Nations and based in Seoul, ... (WHO). Developed for use in developing countries ... to use in a single-dose vial and is ...
... using stem cells, in the hope to replace damaged ... for application in other degenerative conditions. Drs Clare ... Florey Neuroscience Institutes and the University of Melbourne. They ... collaboration being launched at the University of Melbourne today. ...
... Although it can be prevented with a vaccine, roughly 90 ... flu each year, resulting in about 1 million hospital admissions, ... online edition of The Lancet , the research also ... 111,500 children in 2008. According to the report, 99 percent ...
Cached Medicine News:Health News:Horst Sievert, M.D., Ph.D. presented with Master Clinical Operator Award at TCT 2011 2Health News:Helping Others Helps Teens Beat Substance Abuse 2Health News:IVI announces the prequalification of innovative cholera vaccine by the World Health Organization 2Health News:IVI announces the prequalification of innovative cholera vaccine by the World Health Organization 3Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 2Health News:Stem cell research hopes to repair brain damage of Parkinson's disease 3
... Now you can perform stereotactic, ultrasound ... the convenience of your office. Use the ... safer, easier and more clinically advanced method ... its best for the women who trust ...
... perform stereotactic, ultrasound and MRI-guided vacuum assisted ... office. Use the patented, FDA-cleared ATEC system ... clinically advanced method of breast biopsy. Its ... women who trust YOU.,9 Gauge Handpieces: Useful ...
Three-spring evacuator kits with silicone drains, 10 in. hole pattern, trocar and Y-connector tubing...
Offers a more constant suction profile than three-spring evacuators, resulting in the potential for improved tissue approximation and reduced risk of hematoma....
Medicine Products: